Published in Br J Cancer on May 30, 2006
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES. Science (1965) 9.77
Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J Virol (1981) 3.72
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helpervirus dependent parvovirus. Virology (1986) 2.26
Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology (1984) 2.13
Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol (1999) 1.93
Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer (2000) 1.58
Modification of some biological properties of HeLa cells containing adeno-associated virus DNA integrated into chromosome 17. J Virol (1992) 1.45
Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res (2002) 1.34
Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults. Am J Obstet Gynecol (1976) 1.32
Detection of adeno-associated virus type 2 sequences in the human genital tract. J Clin Microbiol (1997) 1.29
Adeno-associated virus inhibits human papillomavirus type 16: a viral interaction implicated in cervical cancer. Cancer Res (1994) 1.19
Detection of adeno-associated virus DNA in human genital tissue and in material from spontaneous abortion. J Med Virol (1994) 1.14
Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst (2003) 1.10
A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer (1996) 1.03
Oligonucleotide primers for DNA amplification of the early regions 1, 6, and 7 from human papillomavirus types 6, 11, 16, 18, 31, and 33. Arch Virol (1991) 0.99
Detection of adeno-associated virus type 2 in human peripheral blood cells. J Gen Virol (1992) 0.98
Altered biology of adeno-associated virus type 2 and human papillomavirus during dual infection of natural host tissue. Virology (2001) 0.97
Adeno-associated virus Rep78 inhibits oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric. Gynecol Oncol (1997) 0.92
High prevalence of adeno-associated virus (AAV) type 2 rep DNA in cervical materials: AAV may be sexually transmitted. Virus Genes (1996) 0.92
Discrimination between different types of human adeno-associated viruses in clinical samples by PCR. J Virol Methods (1998) 0.91
Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia. Exp Mol Pathol (2001) 0.89
Adeno-associated virus and development of cervical neoplasia. J Med Virol (1999) 0.89
Binding of the human papillomavirus type 16 p97 promoter by the adeno-associated virus Rep78 major regulatory protein correlates with inhibition. J Biol Chem (1999) 0.89
Evidence of chromosomal integration of AAV DNA in human testis tissue. Virus Genes (2004) 0.88
Differential suppression of the tumorigenicity of HeLa and SiHa cells by adeno-associated virus. Br J Cancer (1996) 0.86
Adenovirus-associated virus polypeptides synthesized in cells coinfected with either adenovirus or herpesvirus. Virology (1979) 0.82
Evaluation of adenoassociated virus 2 and human papilloma virus 16 and 18 infection in cervical cancer biopsies. Gynecol Oncol (2003) 0.81
Adeno-associated virus DNA in human gestational trophoblastic disease. Placenta (2002) 0.81
Adenovirus-associated (satellite) viruses. Prog Exp Tumor Res (1973) 0.80
Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia. Int J Cancer (2001) 0.80
Evaluation of the possible protective role of adeno-associated virus type 2 infection in HPV-associated premalignant disease of the cervix. Gynecol Oncol (2000) 0.80
Temporal acceleration of the human papillomavirus life cycle by adeno-associated virus (AAV) type 2 superinfection in natural host tissue. Virology (2002) 0.79
Detection of adeno-associated virus DNA in female genital samples by PCR-ELISA. J Med Virol (2001) 0.79
Risk of invasive cervical cancer associated with polymorphic HLA DR/DQ haplotypes. Int J Cancer (2002) 0.79
Development of anticancer gene vaccine interact with human papillomavirus oncoprotein inhibition. Int J Gynecol Cancer (2006) 0.77
General and abdominal adiposity and risk of death in Europe. N Engl J Med (2008) 14.49
European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr (2002) 8.77
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99
Heavy metals in agricultural soils of the Pearl River Delta, South China. Environ Pollut (2002) 3.50
In vivo ultrahigh-resolution optical coherence tomography. Opt Lett (1999) 3.30
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Spectroscopic optical coherence tomography. Opt Lett (2000) 3.12
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Strategies for global control of cervical cancer. Int J Cancer (1995) 2.52
Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia (2011) 2.43
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Underreporting of energy intake in repeated 24-hour recalls related to gender, age, weight status, day of interview, educational level, reported food intake, smoking habits and area of living. Public Health Nutr (2001) 2.37
Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis (2005) 2.35
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst (2000) 2.34
Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations. Diabetologia (2007) 2.23
Fluorescence lifetime imaging in turbid media. Opt Lett (1996) 2.21
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst (1995) 2.01
Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease. Aliment Pharmacol Ther (2014) 2.00
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A (1988) 1.91
Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology (2003) 1.72
Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol (2005) 1.70
Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol (2004) 1.63
Low folate levels may protect against colorectal cancer. Gut (2006) 1.60
Multivariate statistical study of heavy metal enrichment in sediments of the Pearl River Estuary. Environ Pollut (2003) 1.60
Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer (2000) 1.58
Weight change in later life and risk of death amongst the elderly: the European Prospective Investigation into Cancer and Nutrition-Elderly Network on Ageing and Health study. J Intern Med (2010) 1.58
High-yield expression and functional analysis of Escherichia coli glycerol-3-phosphate transporter. Biochemistry (2001) 1.56
Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ (1997) 1.55
Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J Immunol (2001) 1.55
Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. Diabetologia (2012) 1.55
Leptin is associated with increased risk of myocardial infarction. J Intern Med (1999) 1.52
Antibodies against synthetic peptides react with the second Epstein-Barr virus-associated nuclear antigen. EMBO J (1985) 1.48
No serological evidence for non-sexual spread of HPV16. Lancet (1994) 1.47
Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males. An incident case-control study from Sweden. J Intern Med (1998) 1.45
Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Västerbotten cohort project. Stroke (2000) 1.43
A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol (1997) 1.42
An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology (2004) 1.40
Mediterranean diet and type 2 diabetes risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study: the InterAct project. Diabetes Care (2011) 1.39
Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis (1998) 1.39
von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Intern Med (1994) 1.39
[The apparent increase in cancer survival]. Lakartidningen (1995) 1.39
Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer (2008) 1.38
Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA. Int J Cancer (1985) 1.38
Glutamate decarboxylase (GAD65) and tyrosine phosphatase-like protein (IA-2) autoantibodies index in a regional population is related to glucose intolerance and body mass index. Diabetologia (1999) 1.37
Mediterranean dietary pattern and cancer risk in the EPIC cohort. Br J Cancer (2011) 1.35
Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond) (2007) 1.32
HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer (2007) 1.30
Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst (1997) 1.29
Evaluating the discriminative power of multi-trait genetic risk scores for type 2 diabetes in a northern Swedish population. Diabetologia (2010) 1.27
p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis (1996) 1.26
Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol (1999) 1.26
Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer (2007) 1.25
Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis (1990) 1.25
Prevention of cardiovascular disease in Sweden: the Norsjö community intervention programme--motives, methods and intervention components. Scand J Public Health Suppl (2001) 1.24
Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol (2001) 1.23
Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer (2006) 1.23
A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples. J Clin Microbiol (2000) 1.23
Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab (2001) 1.20
Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in Northern Sweden. Stroke (1999) 1.20
Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol (2001) 1.20
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer (2002) 1.20
Regional imager for low-resolution functional imaging of the brain with diffusing near-infrared light. Photochem Photobiol (1998) 1.20
Studies on the rapid detection of Dengue virus antigen by immunofluorescence an radioimmunoassay. Chin Med J (Engl) (1981) 1.19
Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer (1995) 1.19
Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann Rheum Dis (2006) 1.18
Markers of high fish intake are associated with decreased risk of a first myocardial infarction. Br J Nutr (2001) 1.18
Ultrahigh-resolution optical coherence tomography using continuum generation in an air-silica microstructure optical fiber. Opt Lett (2001) 1.17
A population-based seroepidemiological study of cervical cancer. Cancer Res (1994) 1.17
Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol (1999) 1.16
Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol (2008) 1.16
Smoke exposure increases the risk for multiple sclerosis. Eur J Neurol (2008) 1.16
Identification of human papillomavirus seroconversions. J Gen Virol (1995) 1.14
Fatty-acid composition in serum phospholipids and risk of breast cancer: an incident case-control study in Sweden. Int J Cancer (1999) 1.14
Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. Epidemiology (1998) 1.13
Perceived health modifies the effect of biomedical risk factors in the prediction of acute myocardial infarction. An incident case-control study from northern Sweden. J Intern Med (1998) 1.12
Association between the presence of bacterial 16S RNA in prostate specimens taken during transurethral resection of prostate and subsequent risk of prostate cancer (Sweden). Cancer Causes Control (2006) 1.12
Fluorescent diffuse photon density waves in homogeneous and heterogeneous turbid media: analytic solutions and applications. Appl Opt (1996) 1.12